We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Body Fluids-Based Diagnostics to Be Developed and Validated

By LabMedica International staff writers
Posted on 09 Feb 2011
Two new agreements have been made for the development and validation of microRNA-based diagnostics for various indications. More...


The Gen 3 tests will focus on cardiovascular indications, neurodegenerative diseases, women's health, and early detection of certain cancers, and are designed to leverage microRNA biomarkers extracted from body fluids.

A leading developer and provider of microRNA-based molecular diagnostics, Rosetta Genomics (Rehovot, Israel) has entered into agreements with Tel Hashomer Medical Research Infrastructure and Services Ltd (Tel Aviv, Israel) and Carmel Medical Center (Haifa, Israel).

The collaborations are an integral part of Rosetta Genomics' Gen 3 product development process as they utilize the capabilities and samples at these specialized centers to identify initial microRNA candidate biomarkers for the company's discovery-stage projects.

MicroRNAs (miRNAs) are small RNAs that act as master regulators of protein synthesis, and have been shown to be highly effective biomarkers. The unique advantage of microRNAs as biomarkers lies in their high tissue specificity, and their exceptional stability in the most routine preservation methods for biopsies, including Formalin Fixed Paraffin Embedded (FFPE) block tissue and fine needle aspirate (FNA) cell blocks.

"One of Rosetta Genomics' core strengths is our ability to rapidly advance high-value diagnostics through our development engine. Toward that end, we have made significant scientific and technological advances that allow us to optimize the extraction of microRNAs from various body fluids. We are using these capabilities to advance the development of our first body fluids-based tests, which are also our first line of tests outside of oncology," said Kenneth A. Berlin, president and CEO of Rosetta Genomics.

Related Links:

Rosetta Genomics
Tel Hashomer Medical Research Infrastructure and Services Ltd.
Carmel Medical Center



New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Silver Member
Quality Control Material
NATtrol Chlamydia trachomatis Positive Control
New
Silver Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.